Citadel Advisors
PMCB icon

Citadel Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Citadel Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$2.63K – 14503
2025
Q1 		$2.63K Sell
2,100
-2,500
-54% -$4.06K ﹤0.01% 14024
2024
Q4 		$7.13K Buy
+4,600
New +$7.94K ﹤0.01% 13754
2024
Q2 		– Sell
-400
Closed -$948 – 15123
2024
Q1 		$948 Sell
400
-5,200
-93% -$11.3K ﹤0.01% 14215
2023
Q4 		$12.1K Buy
5,600
+4,000
+250% +$8.67K ﹤0.01% 13008
2023
Q3 		$3.36K Sell
1,600
-29,500
-95% -$75.2K ﹤0.01% 13594
2023
Q2 		$88.9K Sell
31,100
-52,900
-63% -$159K ﹤0.01% 11099
2023
Q1 		$244K Buy
84,000
+16,500
+24% +$48.5K ﹤0.01% 9805
2022
Q4 		$197K Buy
67,500
+22,600
+50% +$64.7K ﹤0.01% 10160
2022
Q3 		$108K Sell
44,900
-17,700
-28% -$44.8K ﹤0.01% 11018
2022
Q2 		$141K Buy
+62,600
New +$137K ﹤0.01% 11048
2022
Q1 		– Sell
-26,600
Closed -$67K – 14351
2021
Q4 		$67K Buy
+26,600
New +$73.3K ﹤0.01% 13069

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Citadel Advisors's PMCB Position: Q1 2026 in Review

Citadel Advisors increased its PharmaCyte Biotech (PMCB) stake by 57% in Q1 2026, buying an estimated $99.3K and bringing the position to 359,547 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #11015.

Citadel Advisors first reported a position in PMCB in Q2 2022 and has held it in 10 quarters since. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Citadel Advisors held 359,547 shares of PharmaCyte Biotech worth $239K as of Q1 2026.
  • Citadel Advisors bought 129,825 PharmaCyte Biotech shares in Q1 2026, an estimated $99.3K.
  • PharmaCyte Biotech made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11015 holding.
  • Citadel Advisors first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 10 quarters since.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.